-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest data from Intranet, the sales scale of terminal chemical drugs in public hospitals in key provinces and cities in the first half of 2022 exceeded 100 billion yuan, a slight decline
from the same period last year.
228 brands have sold more than 100 million yuan, with a total sales scale of more than 50 billion yuan, of which 98 brands have risen sharply against the trend, and sales have increased by more than 10% over the same period last year, including 52 domestic brands and 46 imported brands
.
In the first half of 2022, the terminal brands of public hospitals in key provinces and cities exceeded 100 million 98 brands cover 12 treatment categories, focusing on anti-tumor and immunomodulators, systemic anti-infective drugs, blood and hematopoietic system drugs, digestive system and metabolic drugs, etc.
, and the terminal sales scale of these 4 therapeutic categories in public hospitals in key provinces and cities in 2022H1 has exceeded 10 billion yuan
。 The sales of 10 brands exceeded 500 million yuan, and CSPC Group won 3 of the 4 domestic brands, namely polyethylene glycol recombinant human granulocyte stimulating factor injection, paclitaxel (albumin-bound type) for injection and butylphthalide sodium chloride injection; Among the 6 imported brands, Jetbelin led the way with more than 800 million yuan, and AstraZeneca's osimertinib mesylate tablets and Pfizer's cefoperazone sodium sulbactam sodium for injection (2:1) all exceeded 700 million yuan
。 Among the 9 domestic brands, Yichang Dongguang Yangtze River Pharmaceutical's oseltamivir phosphate granules ranked first with a growth rate of 656.
1%, Hainan Simcere Pharmaceutical's edaravone dextrol alcohol injection concentrated solution, and BeiGene's tislelizumab injection increased by more than 300%; Among the 6 imported brands, Biogen's noxinaxen sodium injection ranked first with a growth rate of 852.
13%, and the sales growth rate of Xi'an Janssen's daratumumab injection, Sanofi's dupilumab injection, and Lilly's dulaglutide injection all increased by more than 400%.
01.
Domestic brands: Shiyao leads, Haosen, Simcere and other 1 new drugs are released 52 domestic brands involve 38 pharmaceutical companies (in terms of groups), CSPC Group has 4 exclusive brands, China Biopharmaceutical, Shanghai Pharmaceutical Group, and Yuanda Health all have 3 brands, and BeiGene, Enhua Pharmaceutical, Fosun Pharma, Healthyuan, Simcere Pharmaceutical, and Shijiazhuang Four Yao all have 2 brands listed
。 Pharmaceutical companies with a growth rate of more than 10% and more than 100 million domestic brands 3 of the 4 brands of CSPC have sales of more than 500 million yuan in 2022H1, of which butylphthalide sodium chloride injection is an exclusive variety, in addition to the two major varieties of
paclitaxel (albumin-bound type) for injection and pegylated recombinant human granulocyte stimulating factor injection 。 Among the three brands of Chinese biopharmaceuticals, magnesium isoglycyrrhizate injection is the exclusive variety of Chia Tai Tianqing, with sales of more than 400 million yuan in 2022H1; Abiraterone acetate tablets are the second batch of nationally collected varieties, and Chia Tai Tianqing was selected in the first order, and the sales of public hospital terminals in key provinces and cities have increased
year by year in recent years.
Among the three brands of Shanghai Medicine Group, colistin sulfate for injection and polymyxin sulfate B for injection can be used for drug-resistant bacterial infections, and they are in a dominant position in the market pattern; Among the three brands in East China and China, indobufen tablets are exclusive varieties, and the sales growth rate in 2022H1 is close to 70%.
Among the top 10 domestic brands in 52 domestic brands Among the top 10 domestic brands in sales growth, 9 rose by more than 100%, and Yichang Dongguang Yangtze River Pharmaceutical's oseltamivir phosphate granules led with a growth rate of 656.
10%, which is its exclusive dosage form variety, after the downturn of the previous two years, the market began to warm up; The sales growth rate of domestic Class 1 new drugs such as Hainan Simcere Pharmaceutical's concentrated solution of edafone dextrofenol for injection, BeiGene's tirelizumab injection and zebrutinib capsules, Zai Lab's niraparib tosylate capsules, and Haosen Pharmaceutical's ammetinib mesylate tablets all grew by more than 200%
in 2022H1.
02.
Imported brands: AstraZeneca, Pfizer Baping, 6 major brands soared by more than 100% 46 imported brands involve 21 pharmaceutical companies (in terms of groups), AstraZeneca and Pfizer each have 6 exclusive brands, Bayer has 4 brands on the list, Roche, Merck and Novartis have 3 brands on the list
。 Pharmaceutical companies with a growth rate of more than 10% and more than 100 million imported brands Among the 6 brands of AstraZeneca, no generic drugs have been approved for osimertinib mesylate tablets and olaparib tablets, of which the sales of osimertinib mesylate tablets exceeded 700 million yuan in 2022H1; Rosuvastatin calcium tablets (4+7 and expansion) and omeprazole sodium for injection (seventh batch) have been included in the national procurement, and AstraZeneca was not selected
.
After the centralized harvesting, the sales of AstraZeneca's rosuvastatin calcium tablets fell sharply, and there were signs
of recovery in 2021.
Among Pfizer's 6 brands, atorvastatin calcium tablets and amlodipine besylate tablets were included in 4+7 and expanded collection, and Pfizer was not selected, and the market changes of these two brands were similar to AstraZeneca's rosuvastatin calcium tablets; Among Bayer's 4 brands, no generic drugs have been approved for gofenib tablets and aflixept intraocular injection solution, and moxifloxacin hydrochloride sodium chloride injection has been included in the third batch of national procurement, and Bayer has not been selected
。 Among the 46 imported brands, the growth rate is more than 100% 6 imported brands soared by more than 100%, and Biogen's nocinaxen sodium injection won the "growth rate king", which is a rare disease drug for the treatment of spinal muscular atrophy, which was negotiated into the national Class B medical insurance in 2021; Xi'an Janssen's daratumumab injection is the world's first fully human monoclonal antibody targeting CD38, which was included in the national Class B medical insurance through negotiation in 2021, and no biosimilar drugs have been approved
in China.
03.
Go forward! 9 exclusive brands or new medical insurance On October 16, the National Medical Insurance Bureau issued the "Announcement on the Phased Results of the Expert Review of Declared Drugs Approved by the Formal Review of the National Medical Insurance Drug Catalogue in 2022", which means that the negotiation of national medical insurance in 2022 is
near.
Judging from the list of drugs that passed the preliminary examination released a few days ago, 344 of the 490 declared drugs in the national talks this year have passed the preliminary examination
.
Among the 98 brands, 9 exclusive brands are in the preliminary review list, and 6 of them pass the declaration conditions for condition 2 in the catalogue (negotiated drugs approved by the national drug regulatory department from January 1, 2017 to June 30, 2022, and the indications or functional indications have changed significantly, and other drugs in the catalogue (including the application for adjustment of medical insurance payment scope for drugs renewed in 2022)).
On October 12, the National Medical Insurance Bureau replied to the suggestion of "negotiating drug renewal" put forward by Sun Piaoyang, deputy to the National People's Congress and chairman of Hengrui Pharmaceutical, and Wang Weidong, deputy to the National People's Congress and chairman of Remegen Biopharmaceutical, which highlighted that in order to simplify the negotiation process and improve efficiency, the national medical insurance negotiation this year set up a new "simple renewal" rule, and the new indications have been included in the scope of
simple renewal consideration.
For varieties with new indications, this means that the price reduction will not be too large
.
Among the 98 brands, exclusive varieties appearing in the 2022 medical insurance preliminary review catalogue AstraZeneca's olaparib tablets are the world's first PARP inhibitor approved for marketing, and have obtained 4 indications in China, of which BRCA mutation, HER2-negative metastatic breast cancer and BRCA1/2 mutation metastatic castration-resistant prostate cancer are expected to participate in the new medical insurance negotiations
。 BeiGene's PD-1 monoclonal antibody tirelizumab injection has been approved for 9 indications in China, of which 4 indications for classic Hodgkin lymphoma, urothelial carcinoma, non-small cell lung cancer, and hepatocellular carcinoma have been included in medical insurance through negotiation, and indications such as nasopharyngeal carcinoma and esophageal squamous cell carcinoma are expected to participate in the new medical insurance negotiations
。 Hausen's ammetinib mesylate tablets have been approved for 2 indications, the indications for locally advanced or metastatic non-small cell lung cancer with positive EGFR T790M mutation have been negotiated into medical insurance in 2021, and the indications for the first-line treatment of EGFR-sensitive mutation-positive locally advanced or metastatic non-small cell lung cancer are expected to participate in the new medical insurance negotiations
.
Source: Intranet database, National Health Insurance Administration, etc
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
